Gbola Amusa
Stock Analyst at Chardan Capital
(1.32)
# 2,899
Out of 4,667 analysts
61
Total ratings
34.78%
Success rate
-2.78%
Average return
Main Sectors:
Stocks Rated by Gbola Amusa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $6.12 | +716.99% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $60 → $68 | $2.02 | +3,241.58% | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | $2,875 → $2,625 | $11.65 | +22,437.99% | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | $188 → $300 | $5.20 | +5,669.23% | 5 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | $36 → $45 | $0.52 | +8,514.09% | 3 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | $28 → $30 | $0.76 | +3,873.51% | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | $85 → $100 | $5.68 | +1,660.56% | 4 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | $75 → $150 | $1.42 | +10,463.38% | 2 | Jan 13, 2021 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $53 → $50 | $8.27 | +504.59% | 3 | Oct 6, 2020 | |
| IMVT Immunovant | Maintains: Buy | $35 → $45 | $26.19 | +71.82% | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $115 | $176.62 | -34.89% | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $100 | $46.09 | +116.97% | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $36.62 | +159.43% | 2 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $15 | $9.47 | +58.39% | 4 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $130 | $9.21 | +1,312.28% | 4 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $100 | $2.42 | +4,040.79% | 6 | Mar 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $2.5 → $2 | $636.60 | -99.69% | 2 | Jan 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $4.94 | - | 3 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $300 → $350 | $745.19 | -53.03% | 6 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $6.12
Upside: +716.99%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: $60 → $68
Current: $2.02
Upside: +3,241.58%
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: $2,875 → $2,625
Current: $11.65
Upside: +22,437.99%
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: $188 → $300
Current: $5.20
Upside: +5,669.23%
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: $36 → $45
Current: $0.52
Upside: +8,514.09%
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: $28 → $30
Current: $0.76
Upside: +3,873.51%
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: $85 → $100
Current: $5.68
Upside: +1,660.56%
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: $75 → $150
Current: $1.42
Upside: +10,463.38%
Iovance Biotherapeutics
Oct 6, 2020
Maintains: Buy
Price Target: $53 → $50
Current: $8.27
Upside: +504.59%
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: $35 → $45
Current: $26.19
Upside: +71.82%
Aug 19, 2020
Maintains: Buy
Price Target: $100 → $115
Current: $176.62
Upside: -34.89%
Jul 28, 2020
Maintains: Buy
Price Target: $73 → $100
Current: $46.09
Upside: +116.97%
Jul 15, 2020
Maintains: Buy
Price Target: $84 → $95
Current: $36.62
Upside: +159.43%
Aug 17, 2018
Downgrades: Neutral
Price Target: $19 → $15
Current: $9.47
Upside: +58.39%
Jul 16, 2018
Maintains: Buy
Price Target: $90 → $130
Current: $9.21
Upside: +1,312.28%
Mar 27, 2018
Maintains: Neutral
Price Target: $75 → $100
Current: $2.42
Upside: +4,040.79%
Jan 10, 2018
Upgrades: Neutral
Price Target: $2.5 → $2
Current: $636.60
Upside: -99.69%
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $4.94
Upside: -
Dec 12, 2016
Upgrades: Neutral
Price Target: $300 → $350
Current: $745.19
Upside: -53.03%